B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
PTGX
Protagonist TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$107.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$72.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+26.8
Score
AI commentary
Sentiment stays cautiously constructive, but this should remain a monitoring-style memo rather than a high-conviction bullish call. Primary sources improved the setup with ICOTYDE approval on March 18, 2026 and the rusfertide opt-out election on April 28, 2026, both of which support non-dilutive economics and partner-led commercialization [#PR-2026-03-18] [#PR-2026-04-28]. However, the scheduled May 4, 2026 post-earnings follow-up did not yield a confirmed Q1 2026 earnings release or analyst revision signal in checked company/SEC sources, so there is no fresh earnings-surprise evidence to upgrade conviction. PTGX traded about 1.1% above the May 1 anchor price during May 4 trading, which looks more like steady event-driven positioning than a decisive post-print reaction.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-31catalystRusfertide opt-out election materially changes near-term cash and launch-risk profileHigh impact
On April 28, 2026, Protagonist said it exercised its rusfertide U.S. opt-out right with Takeda, making it eligible for $200 million upon the election, another $200 million upon U.S. approval, plus a $75 million approval milestone, while shifting U.S. commercialization responsibility to Takeda; that sharpens the near-term setup but still needs conversion into received cash and eventual approval [#PR-2026-04-28].
2026-09-30eventRusfertide FDA decision remains the main binary re-rating eventHigh impact
The April 28, 2026 company update said rusfertide remains under FDA Priority Review for adults with polycythemia vera with a PDUFA target action date in the third quarter of 2026; approval would unlock the second opt-out payment and a further approval milestone, while a delay or rejection would hit the core thesis [#PR-2026-04-28].
2026-12-31catalystICOTYDE approval adds a second partnered royalty-and-milestone growth legHigh impact
Protagonist disclosed on March 18, 2026 that FDA approved ICOTYDE for moderate-to-severe plaque psoriasis, triggering a $50 million milestone and leaving Protagonist eligible for 6% to 10% royalties plus up to $580 million of additional milestones; if launch uptake and follow-on indication studies progress, this can diversify value away from a single rusfertide outcome over time [#PR-2026-03-18].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology